Incentive shares are a positive and strategic element of...

Incentive shares are a positive and strategic element of corporate governance, particularly in the context of OncoSil Medical's CEO potentially receiving 91.5 million performance rights under the company's Omnibus Plan. These rights are intelligently structured, divided into four segments, each contingent on achieving specific, meaningful milestones.

This approach aligns the CEO's interests with those of the company and its stakeholders, fostering a focused and goal-oriented leadership.

First Hurdle - PANCOSIL Clinical Trial Enrollment: The first chunk of rights is awarded when the 50th patient is enrolled in the PANCOSIL clinical trial. This milestone is significant as it demonstrates progress in clinical development, a critical factor for potential partners. Easier application of OncoSil™ becomes more commercially viable, simplifying rollout strategies and enhancing market appeal.

Second Hurdle - G-BA Clinical Trial Commencement: The initiation of the G-BA clinical trial, with all necessary approvals and management in place, signifies that the concept has been proven and is ready for a broader test. This milestone is vital for confirming the efficacy and potential of OncoSil™, increasing confidence among stakeholders.

Third Hurdle - Sales of 100 OncoSil™ Devices: Achieving sales of 100 devices within a year, potentially generating $2 million (at AUD 20,000 each), is not just a financial milestone but also an indicator of market acceptance and demand. This level of sales performance reflects the product's commercial value and operational success.

Fourth Hurdle - Sales of 200 OncoSil™ Devices: Selling 200 devices in a single year (or achieving this goal directly without first hitting the 100-device target) signifies an even stronger market presence and commercial success, potentially bringing in about $4 million.

These structured performance goals ensure that the CEO's rewards are directly tied to tangible achievements that benefit the company. This approach motivates focused effort towards specific targets that are crucial for the company's growth and success. It also offers transparency and accountability, providing clear indicators of progress to investors and partners. By setting these hurdles, OncoSil Medical ensures that its leadership is not just rewarded for their efforts but for achieving outcomes that significantly advance the company's objectives and value.